HealthXL and Almirall were lucky to have had a chance to run this event back in February in person in Barcelona prior to the COVID-19 escalation, and wish everybody in Spain and beyond well during these tough times. Below is a roundup of the discussions we had with some of the prominent leaders in
What we learned at this year’s HealthXL Global Gathering. At this year’s gathering, two key themes dominated the discussions of the day:Clinical Trial Optimization: What are the barriers and opportunities? How do we sequence evidence generation within the field of digital therapeutics?
This is your monthly digest of three noteworthy news stories in digital health from the past month - what they mean for the industry, and why you should know about them.
Chris Coburn, Partners Healthcare and an old friend of HealthXL talks to us about how growing up in a large healthcare family and the journey that led him to his current role as Chief Innovation Officer.
This week, in collaboration with HealthXL member Jeff Gombala (ZS Associates), we discuss the potential of digital health solutions to address the social determinants of health.
It’s time for your monthly digital health news dose. We have looked back at three of the most noteworthy pieces of news from the last month and distilled what they mean for the industry and the key takeaways you should have on your radar. Interested in getting beyond the headlines?
The Digital Health Evidence Review 2019 report aims to identify, categorize, and summarize all existing, relevant studies in digital health. In this report, we have to established a clear understanding of the existing body of clinical evidence for digital health, its maturity, current gaps and needs
Take an indepth look into what we will be exploring during our September events in Dublin and Shanghai. Two very different formats, both with exceptionally great people speaking and attending.
Eugene Borukhovich is disrupting healthcare! In this episode you will learn why, how and what is driving him. He unveils his thoughts on the American PBM model, on changing dynamics, innovative pharma companies, margins on digital health assets, his favorite start-ups and more!
The HealthXL platform was launched this month, in this blog we discuss why we built it, how our members use it today and our vision for where we’re taking it next.
A monthly digest of three noteworthy news stories in digital health from the past month - what they mean for the industry, and why you should know about them.
Megan is the Founder and Executive Director of the Digital Therapeutics Alliance (DTA). The DTA has really taken off in the last few years as the cohort of industry leaders and stakeholders engaged in the evidence-driven advancement of digital therapeutics.
Our upcoming HealthXL Research report aims to identify, categorize, and summarize all existing, relevant studies in digital health. Through this report, we want to establish a clear understanding of the existing body of clinical evidence for digital health, its maturity, current gaps, and needs.
People living with addiction disorders have long been an underserved population in healthcare. This week we look at how digital tools are supporting accessible and unbiased support for smoking cessation, opioid use disorders, and alcoholism.
An analysis of the consumer diagnostic space, looking at the top funded companies, partnerships, notable activity etc, using the data from our HealthXL platform. We explore the biggest companies that are selling diagnostic kits direct to consumer.
Three noteworthy news stories in digital health from the past month - what they mean for the industry, and why you should know about them.
Episode #2 of the HealthXL podcast meets with Robert Garber of 7wire ventures. The conversation spins from lessons learned to life hacks that shaped his career and how he does business today .
60% of China’s 1.4 Billion population will be living in an urban setting by 2030, so their pole position on the smart cities front is hardly surprising. What are some of the notable activity happening on the ground and to what extent can these efforts help improve population health outcomes?
In this weeks blog, we are doing a roundup of some notable investments that have occurred so far in 2019, assessing the types of companies that are catching the interest of investors, and exploring if these correlate to our previous predictions or if there are any new trends to add to your radar.
Moving past investments in digital health, we are now starting to be asked about returns.What is the ROI on Digital Health? Return on investment (ROI) is king in every sector, healthcare not spared and we want to see finacial results.
Episode #1 of HealthXL's Digital Health podcast, featuring Bill Zeruld from Otsuka Pharmacueticals.
There are 3.3 million unique genes in the human gut, 150 times more genes than the human genome - basically, we are more microbiome than we are human. This week we take a dive into the flourishing microbiome space and digital interventions supporting its scale to supercharge personalized healthcare.
We recently released our Q1 report on Virtual Health Assistants (VHAs). As part of the report, we carried out a survey on consumers and clinicians. In this weeks blog, we examine the results of our survey to gain an insight into consumer and clinician awareness, adoption, and trust in VHAs.
Primary care is the healthcare provided in the community for people making an initial approach to a medical practitioner or clinic for advice or treatment and it's undergoing major change internationally. In this blog we explore how digital can support and improve the delivery of care.
Our report on Virtual Health Assistants (VHA). The report looks at the investment landscape, clinical evidence, and regulatory environment for VHAs, and also explores end-user feedback and case studies looking at both the positives and negatives of VHAs.